Comparative Pharmacology
Head-to-head clinical analysis: HYGROTON versus NATURETIN 2 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYGROTON versus NATURETIN 2 5.
HYGROTON vs NATURETIN-2.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive sodium-chloride cotransporter (NCC), leading to increased excretion of sodium, chloride, and water.
Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
25-50 mg orally once daily; may increase to 100 mg once daily for resistant hypertension or edema. Maximum dose 100 mg/day.
Hypertension: 2.5 mg orally once daily; may increase to 5 mg daily if needed. Edema: 2.5 to 10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 40-50 hours, extending up to 70 hours in patients with renal impairment, allowing for once-daily dosing.
Terminal elimination half-life: 6-9 hours; prolonged in renal impairment and in elderly patients.
Renal (approximately 50-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for a minor fraction, less than 10%.
Renal excretion: approximately 95% as unchanged drug; biliary/fecal: <5%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic